HC Wainwright reaffirmed their buy rating on shares of Pharming Group (NASDAQ:PHAR – Free Report) in a research report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $37.00 price objective on the stock.
Pharming Group Trading Up 5.1 %
Shares of PHAR traded up $0.42 during mid-day trading on Thursday, hitting $8.72. 2,626 shares of the company’s stock traded hands, compared to its average volume of 4,869. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $591.48 million, a P/E ratio of -45.89 and a beta of 0.15. The business’s 50-day moving average price is $8.03 and its 200-day moving average price is $8.56. Pharming Group has a 1 year low of $6.65 and a 1 year high of $13.20.
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The company had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. During the same period in the previous year, the firm posted $0.02 earnings per share. As a group, sell-side analysts forecast that Pharming Group will post -0.15 EPS for the current fiscal year.
Institutional Trading of Pharming Group
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Articles
- Five stocks we like better than Pharming Group
- How to Invest in Biotech Stocks
- Texas Roadhouse Stock Steering for New Highs This Year
- Consumer Discretionary Stocks Explained
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.